Medicsensors, which trades as Medicsen and was incorporated in Madrid in 2015, has developed the Smartpatch, a wearable device about the size of a matchbox that uses low-frequency ultrasound to open skin pores temporarily so that large drug molecules such as insulin can pass through the skin without a needle. It was selected in the EIC Accelerator's January 2023 cut-off and received an EU grant of €2.50 million for a €3.84 million project that ran from August 2023 to May 2026, according to CORDIS. The project "focuses on the full commercialization of Medicsen Smartpatch".
The project is closed, and CORDIS holds only its first periodic report, to July 2024, which said the project was "advancing successfully in its full clinical trials towards achieving CE labelling", according to the CORDIS reporting page. The first human study, SOUNDD, began on 20 January 2026 at Hospital Universitario Ramón y Cajal in Madrid with 30 healthy volunteers, comparing the patch with a subcutaneous injection, and is estimated to complete in November 2026, according to ClinicalTrials.gov. No CE mark has been announced.
Company file
- Legal entity
- Medicsensors SL, Madrid
- Incorporated
- 26 August 2015
- Board chair and company head
- Eduardo Jorgensen
- Product
- Medicsen Smartpatch (sonophoresis)
- Target drugs
- Insulin, teriparatide, GLP-1 analogues, adalimumab
- Turnover
- €500,000 to €1M, per register data
- EIC funding
- Grant first
Where Medicsen Stands Now
Eduardo Jorgensen, the medical doctor who leads the company, told Deepsync that by early 2023 the company "only had enough money to cover a few more weeks", that it had approached a thousand investors, and that the EIC grant arrived "three days before we were going to tell the team they might have to find new jobs", after twelve failed applications. The grant paid for GLP studies in pigs and preparation for human trials, which he expected to begin in late 2025; they began in January 2026. Medicsen now targets insulin, the osteoporosis drug teriparatide, GLP-1 drugs such as Ozempic, and adalimumab.
"We had failed twelve times before with EIC applications, but we learned, we evolved, and on the thirteenth try we got it."
Eduardo Jorgensen, Medicsen, to DeepsyncThe Technology: Opening Skin With Sound
Low-frequency ultrasound creates tiny bubbles in the skin that expand and collapse, briefly opening pathways that let molecules up to 200 kDa through; the pores close when the device stops, the company says. The patch has a reusable electronic core that lasts up to three years and a disposable drug reservoir. In unpublished trials, it delivered insulin and teriparatide through pig skin with absorption comparable to injections, Jorgensen said.
What the EIC Award Promised, and What the Record Shows
The award aimed at full commercialisation and clinical trials towards a CE mark. The EIC money kept the company alive and got the patch into its first human study, in healthy volunteers rather than patients. There is no CE mark, no published human data yet and no public final report.
- Miniaturised deviceDeliveredMatchbox-sized patch.
- GLP animal studiesDeliveredIn pigs, per CEO.
- Human trialsStarted30 volunteers, 2026.
- CE mark and launchNot yetNot announced.
The Money
Medicsen's annual turnover is between €500,000 and €1 million, according to Spanish register data summarised by Empresia, whose latest filed accounts are for 2024. Its share capital was €7,050 after a 2022 increase. Its investors and losses could not be checked from free sources.
What Cannot Be Checked
Questions for the EIC
What the final report says, what the SOUNDD study found, when a CE mark will be sought, and where Medicsen's revenue comes from are not public.
Why Europe Should Care
Deepsync reports that Europe has the world's highest burden of type 1 diabetes, and the company's report says needle fatigue drives poor adherence to treatment. A painless patch for insulin or GLP-1 drugs would reach a very large market. Medicsen's story also shows the EIC acting as a funder of last resort for a company private investors would not back without human data.
What the award promised
Full commercialisation of a needle-free, wearable drug delivery patch, with clinical trials towards a CE mark.
What the record shows
A first study in 30 healthy volunteers, due to finish after the project, and no CE mark.
The Verdict
Rescued, not yet proven
The EIC grant saved Medicsen and moved its patch into human testing. The commercial product the project promised is still some way off.
Medicsen and the EIC have not been asked for comment for this article. It is based entirely on public records and published statements, linked throughout.
